Improvement of Adeno-Associated Virus-Mediated Liver Transduction Efficacy by Regional Administration in Macaca fascicularis.

Q1 Medicine
Human Gene Therapy Clinical Development Pub Date : 2017-06-01 Epub Date: 2017-03-10 DOI:10.1089/humc.2016.183
Nerea Zabaleta, David Salas, Maria Paramo, Mirja Hommel, Valerie Sier-Ferreira, Ruben Hernandez-Alcoceba, Jesus Prieto, Jose I Bilbao, Gloria Gonzalez-Aseguinolaza
{"title":"Improvement of Adeno-Associated Virus-Mediated Liver Transduction Efficacy by Regional Administration in Macaca fascicularis.","authors":"Nerea Zabaleta,&nbsp;David Salas,&nbsp;Maria Paramo,&nbsp;Mirja Hommel,&nbsp;Valerie Sier-Ferreira,&nbsp;Ruben Hernandez-Alcoceba,&nbsp;Jesus Prieto,&nbsp;Jose I Bilbao,&nbsp;Gloria Gonzalez-Aseguinolaza","doi":"10.1089/humc.2016.183","DOIUrl":null,"url":null,"abstract":"<p><p>The liver is a central organ in metabolism and can be affected by numerous inherited metabolic disorders. Recombinant adeno-associated virus (AAV)-based gene therapy represents a promising therapeutic approach for such diseases. AAVs have been demonstrated to be safe, and resulted in high and long-term expression in preclinical and clinical studies. However, there are still some concerns regarding the expression levels that can be achieved and the percentage of hepatocytes that can be transduced. Because of the cell-autonomous nature of most metabolic liver disorders, a high percentage of hepatocytes needs to be corrected in order to achieve a therapeutic effect. The goal of our work was to improve transduction efficacy of the liver by conveying the vector directly to hepatic tissue. Interventional radiology procedures were used to administer an AAV5 vector expressing a secreted form of human embryonic alkaline phosphatase (hSEAP) under the control of a liver-specific promoter to a clinically relevant animal model, Macaca fascicularis. Balloon occlusion of the regional hepatic venous flow was performed while injecting the vector either into the hepatic artery (HA) or, against flow, via the suprahepatic vein (SHV). In both cases the vector was injected into the right hepatic lobules, and the two routes were compared with conventional intravenous administration. Higher hSEAP levels were obtained when the vector was administered via SHV or HA than after intravenous injection. Furthermore, higher expression levels correlated with a higher number of vector genomes in the injected lobules. In conclusion, direct administration of AAV vectors via the hepatic blood flow with simultaneous balloon occlusion of the hepatic outflow increases liver transduction efficacy in comparison with systemic delivery and can be further improved in bigger animals or humans, where it would be technically feasible to inject the vector into the hepatic vasculature in the generality of lobules.</p>","PeriodicalId":51315,"journal":{"name":"Human Gene Therapy Clinical Development","volume":"28 2","pages":"68-73"},"PeriodicalIF":0.0000,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/humc.2016.183","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Gene Therapy Clinical Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/humc.2016.183","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/3/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 8

Abstract

The liver is a central organ in metabolism and can be affected by numerous inherited metabolic disorders. Recombinant adeno-associated virus (AAV)-based gene therapy represents a promising therapeutic approach for such diseases. AAVs have been demonstrated to be safe, and resulted in high and long-term expression in preclinical and clinical studies. However, there are still some concerns regarding the expression levels that can be achieved and the percentage of hepatocytes that can be transduced. Because of the cell-autonomous nature of most metabolic liver disorders, a high percentage of hepatocytes needs to be corrected in order to achieve a therapeutic effect. The goal of our work was to improve transduction efficacy of the liver by conveying the vector directly to hepatic tissue. Interventional radiology procedures were used to administer an AAV5 vector expressing a secreted form of human embryonic alkaline phosphatase (hSEAP) under the control of a liver-specific promoter to a clinically relevant animal model, Macaca fascicularis. Balloon occlusion of the regional hepatic venous flow was performed while injecting the vector either into the hepatic artery (HA) or, against flow, via the suprahepatic vein (SHV). In both cases the vector was injected into the right hepatic lobules, and the two routes were compared with conventional intravenous administration. Higher hSEAP levels were obtained when the vector was administered via SHV or HA than after intravenous injection. Furthermore, higher expression levels correlated with a higher number of vector genomes in the injected lobules. In conclusion, direct administration of AAV vectors via the hepatic blood flow with simultaneous balloon occlusion of the hepatic outflow increases liver transduction efficacy in comparison with systemic delivery and can be further improved in bigger animals or humans, where it would be technically feasible to inject the vector into the hepatic vasculature in the generality of lobules.

区域给药提高腺相关病毒介导的束状猕猴肝脏转导效果。
肝脏是代谢的中枢器官,可受许多遗传性代谢疾病的影响。基于重组腺相关病毒(AAV)的基因治疗是治疗此类疾病的一种很有前途的方法。在临床前和临床研究中,aav已被证明是安全的,并导致高表达和长期表达。然而,对于可实现的表达水平和可转导的肝细胞百分比仍然存在一些担忧。由于大多数代谢性肝脏疾病的细胞自主性质,为了达到治疗效果,需要纠正高比例的肝细胞。我们工作的目标是通过将载体直接传递到肝组织来提高肝脏的转导效率。采用介入放射学方法,将在肝脏特异性启动子控制下表达人胚胎碱性磷酸酶(hSEAP)分泌形式的AAV5载体注射到临床相关动物模型——束状猕猴。在将载体注入肝动脉(HA)或逆流注入肝上静脉(SHV)时,球囊闭塞局部肝静脉流。在这两种情况下,载体注射到右肝小叶,并与常规静脉给药途径进行比较。通过SHV或HA给药的hSEAP水平高于静脉注射。此外,在注射的小叶中,较高的表达水平与较高的载体基因组数量相关。综上所述,与全身给药相比,通过肝血流直接给药AAV载体,同时球囊阻断肝流出液,可以提高肝转导的效果,并且在更大的动物或人类中可以进一步提高,在这些动物或人类中,在技术上可行的是将载体注射到肝血管中,一般是小叶。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Human Gene Therapy Clinical Development
Human Gene Therapy Clinical Development CRITICAL CARE MEDICINEMEDICINE, RESEARCH &-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
7.20
自引率
0.00%
发文量
0
期刊介绍: Human Gene Therapy (HGT) is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes important advances in DNA, RNA, cell and immune therapies, validating the latest advances in research and new technologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信